Target intelligence / Profile preview

Inositol 1,4,5-trisphosphate (IP₃ (InsP₃))

Target
IP₃ (InsP₃)
Molecular classification
Other (Second messenger), Inositol phosphate, Small molecule
01

Overview

Inositol 1,4,5-trisphosphate (IP₃) is an important small molecule second messenger produced by the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂) via phospholipase C following activation of G protein-coupled or tyrosine kinase receptors. IP₃ diffuses through the cytosol, binding to and activating inositol trisphosphate receptors, which are calcium channels embedded in the endoplasmic reticulum membrane. This interaction triggers the release of Ca²⁺ from ER stores, thereby facilitating numerous cellular responses including metabolism, secretion, cell proliferation, differentiation, apoptosis, and neuronal signaling. IP₃ is rapidly metabolized by specific kinases and phosphatases, tightly controlling calcium signaling. While not a therapeutic target itself, dysregulation of the IP₃ pathway is implicated in several disease states including neuropsychiatric and neurodegenerative conditions. Note: For structured entries regarding a therapeutic target, you should refer to "Inositol 1,4,5-trisphosphate receptor" (IP₃ receptor), which is the actual protein targeted by drugs and serves as the receptor for IP₃.

Other names
Inositol 1,4,5-trisphosphateIP₃InsP₃Ins3PIP3
02

Mechanism of action

Second messenger: Binds to the inositol trisphosphate receptor, causing Ca²⁺ release from the endoplasmic reticulum; Indirect drug modulation: Drugs target upstream or downstream enzymes/receptors, not the IP₃ molecule itself

03

Biological functions

Signal transductionMobilization of intracellular calciumRegulation of metabolism, secretion, fertilization, proliferation, cell growth, transformation, differentiation, cell death, and neuronal signaling
04

Disease associations

Neurological disorders (indirectly)Bipolar disorder (due to disruption of inositol signaling)Alzheimer's diseaseHuntington's diseaseAmyotrophic lateral sclerosis (ALS)Cancer (via cell proliferation pathways)Cardiovascular disease (via Ca²⁺ signaling)Other (due to involvement in multiple signaling cascades)
05

Interacting drugs

Lithium (indirect inhibitor of pathway via inositol monophosphatase inhibition)

1 more in the full profile.

Beyond the preview

Go deeper on Inositol 1,4,5-trisphosphate (IP₃ (InsP₃)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inositol 1,4,5-trisphosphate (IP₃ (InsP₃)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call